Drug treats hepatitis C by targeting body's RNA

03/27/2013 | Science News

A new drug for hepatitis C attacks RNA that allows the virus to hide from the immune system. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially be used in other serious diseases, including cancer. "This is really a revolution in science, and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for research on RNA.

View Full Article in:

Science News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ